Eylea HD improved vision with extended dosing intervals in patients with macular edema following retinal vein occlusion in the phase 3 QUASAR trial, according to a press release from Regeneron.
Patients underwent treatment with Eylea HD (aflibercept 8 mg) every 8 weeks after three (293 patients) or five (298 patients) initial monthly doses, while a control group underwent treatment with Eylea 2 mg every 4 weeks (301 patients). The study met its primary endpoint at 36 weeks, with both Eylea HD groups achieving noninferior visual acuity gains compared with the (Read more...)